Response of MUTZ-3 dendritic cells to the different components of the haemophilus influenzae type b conjugate vaccine: Towards an in vitro assay for vaccine immunogenicity

Vaccine

Volumn 29, Issue 32, 2011, Pages 5114-5121

  Hoefnagel, Marcel H N ^a   Vermeulen, Jolanda P ^a   Scheper, Rik J ^b   Vandebriel, Rob J ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; Haemophilus influenzae type B; Immunogenicity; In vitro assay; MUTZ 3

Indexed keywords

BIOLOGICAL MARKER; CD209 ANTIGEN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; OUTER MEMBRANE PROTEIN; POLYRIBOSYL RIBITOL PHOSPHATE; POLYRIBOSYL RIBITOL PHOSPHATE OUTER MEMBRANE PROTEIN CONJUGATE; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG CONJUGATION; DRUG EFFECT; DRUG POTENCY; EX VIVO STUDY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MONOCYTE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; CELL LINE; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; POLYSACCHARIDES; POLYSACCHARIDES, BACTERIAL; VACCINES, CONJUGATE;

EID: 79960295579     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.050     Document Type: Article

References (21)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. van Helden S.F., van Leeuwen F.N., Figdor C.G. Human and murine model cell lines for dendritic cell biology evaluated. Immunol Lett 2008, 117:191-197.
3. Masterson A.J., Sombroek C.C., de Gruijl T.D., Graus Y.M., van der Vliet H.J., Lougheed S.M., et al. MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood 2002, 100:701-703.
4. Santegoets S.J., Masterson A.J., van der Sluis P.C., Lougheed S.M., Fluitsma D.M., van den Eertwegh A.J., et al. A CD34(+) human cell line model of myeloid dendritic cell differentiation: evidence for a CD14(+)CD11b(+) Langerhans cell precursor. J Leukoc Biol 2006, 80:1337-1344.
5. Larsson K., Lindstedt M., Borrebaeck C.A. Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells. Immunology 2006, 117:156-166.
6. Schoeters E., Verheyen G.R., Van Den Heuvel R., Nelissen I., Witters H., Van Tendeloo V.F., et al. Expression analysis of immune-related genes in CD34(+) progenitor-derived dendritic cells after exposure to the chemical contact allergen DNCB. Toxicol In Vitro 2005, 19:909-913.
7. Heath P.T. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998, 17:S117-S122.
8. Kayhty H., Karanko V., Peltola H., Makela P.H. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984, 74:857-865.
9. Donnelly J.J., Deck R.R., Liu M.A. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Immunol 1990, 145:3071-3079.
10. Liu M.A., Friedman A., Oliff A.I., Tai J., Martinez D., Deck R.R., et al. A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes. Proc Natl Acad Sci USA 1992, 89:4633-4637.
11. Kim K.D., Choi S.C., Noh Y.W., Kim J.W., Paik S.G., Yang Y., et al. Impaired responses of leukemic dendritic cells derived from a human myeloid cell line to LPS stimulation. Exp Mol Med 2006, 38:72-84.
12. Latz E., FrankoJ, Golenbock D.T., Schreiber J.R. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 2004, 172:2431-2438.
13. Perez-Melgosa M., Ochs H.D., Linsley P.S., Laman J.D., van Meurs M., Flavell R.A., et al. Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine. Eur J Immunol 2001, 31:2373-2381.
14. Geijtenbeek T.B., den Dunnen J., Gringhuis S.I. Pathogen recognition by DC-SIGN shapes adaptive immunity. Future Microbiol 2009, 4:879-890.
15. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589:1-13.
16. Tsai C.M., Frasch C.E., Rivera E., Hochstein H.D. Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J Biol Stand 1989, 17:249-258.
17. Re F., Strominger J.L. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol 2004, 173:7548-7555.
18. Re F., Strominger J.L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001, 276:37692.
19. Goriely S., Molle C., Nguyen M., Albarani V., Haddou N.O., Lin R., et al. Interferon regulatory factor 3 is involved in Toll-like receptor 4 (TLR4)- and TLR3-induced IL-12p35 gene activation. Blood 2006, 107:1078-1084.
20. Rasaiyaah J., Noursadeghi M., Kellam P., Chain B. Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line. Immunology 2009, 127:429-441.
21. Nelissen I., Selderslaghs I., Heuvel R.V., Witters H., Verheyen G.R., Schoeters G. MUTZ-3-derived dendritic cells as an in vitro alternative model to CD34+ progenitor-derived dendritic cells for testing of chemical sensitizers. Toxicol In Vitro. 2009, 23:1477-1481.